Related Links
ARALAST NP Therapy
Choose a therapy that offers support for your patients.
ARALAST NP AATmosphere Program
Support for Alphas and families from the ARALAST NP AATmosphere program.
Home Care
ARALAST NP therapy is available through nationwide homecare services for patient convenience.
It's easy to start patients on ARALAST NP therapy. Four of the nation’s leading specialty pharmacies can dispense ARALAST NP therapy to your patients. They are:
Accredo Therapeutics
1-866-6ALPHA1 (866-625-7421)
www.accredotx.com
PrecisionRx Specialty Solutions
1-866-468-5787
www.precisionrxspecialtysolutions.com
Caremark Inc.
1-800-237-2767
www.caremark.com
Coram Healthcare
1-866-FOR-A1PI (866-367-2174)
www.coramhc.com
Comprehensive in-home care
- Patients are cared for by a team of highly qualified, experienced pharmacists, nurses, and client representatives
Education and nursing support
- Professional resources for all therapy options, from self infusion to nurse administered
- Convenience within the patient's home or workplace
Advocacy programs
- Case managers work with patients to advocate for access to benefits and to identify and secure appropriate reimbursment levels
- Provide information on insurance issues and state programs
Nurse-to-physician information
- Regular communication with physician ensures quality patient care
Nationwide service
- Comprehensive service whenever patients need therapy
ARALAST NP therapy is also available in hospital/infusion suites for Medicare recipients.
If you or your patients have questions about accessing therapy with ARALAST NP therapy, call 1-866-ARALAST (272-5278).
These links are provided for your convenience. However, they lead to external websites not created, managed, or maintained by Baxter. Baxter is not responsible for, and does not necessarily endorse, the opinions or products represented on these external pages.
ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]
ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.
The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.
Please review the Important Risk Information and the Full Prescribing Information
Please review the Important Risk Information and the Full Prescribing Information
